Geneva, March 23 -- International Clinical Trials Registry received information related to the study (NCT07453342) titled 'Immune-Related Adverse Events After Cancer Immunotherapy and Safety of Treatment Rechallenge' on March 1.

Study Type: Observational

Primary Sponsor: Peking Union Medical College Hospital

Condition: Immune-Related Adverse Events

Intervention: Drug: Immune Checkpoint Inhibitors

Recruitment Status: Recruiting

Date of First Enrollment: January 1, 2023

Target Sample Size: 500

Countries of Recruitment: China

To know more, visit https://clinicaltrials.gov/study/NCT07453342

Published by HT Digital Content Services with permission from Health Daily Digest....